Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidades: FCF, IQ
Subjects: ARTERIOSCLEROSE, ESTRESSE OXIDATIVO, ÁCIDOS GRAXOS OMEGA 3, NANOTECNOLOGIA
ABNT
LEÃO, Matheus de Castro et al. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, v. 159, p. 99–107, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2020.12.016. Acesso em: 20 ago. 2024.APA
Leão, M. de C., Pohlmann, A. R., Alves, A. de C. S., Farsky, S. H. P., Uchiyama, M. K., Araki, K., et al. (2021). Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, 159, 99–107. doi:10.1016/j.ejpb.2020.12.016NLM
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016Vancouver
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016